| + |
SOX4 | up-regulates activity 
binding
|
CTNNB1 |
0.576 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-256139 |
|
|
Homo sapiens |
Pro-B-lymphocyte |
| pmid |
sentence |
| 24970928 |
The findings in this study raise the possibility that Sox4 may also antagonize Lef1 (Tcf1 is not expressed in pro-B lymphocytes) function by controlling the stability of β-catenin in pro-B lymphocytes. |
|
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-256138 |
|
|
Homo sapiens |
SW-480 Cell |
| pmid |
sentence |
| 17875931 |
We have demonstrated that Sox17 and Sox4 can directly interact with β-catenin and TCF/LEF proteins.Sox4 enhances β-catenin/TCF activity and the proliferation of SW480 cells.In contrast, Sox4 may function to stabilize β-catenin protein. |
|
| Publications: |
2 |
Organism: |
Homo Sapiens |
| Pathways: | Acute Myeloid Leukemia, AML1-ETO in AML, FLT3 in AML |
| + |
FOXC1 | up-regulates quantity by expression 
transcriptional regulation
|
SOX4 |
0.326 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-275917 |
|
|
|
|
| pmid |
sentence |
| 31650548 |
Therefore, FOXC1 is strongly suggested as a pro-metastatic gene in CRC by transcriptionally activating MMP10, SOX4 and SOX15 |
|
| Publications: |
1 |
| + |
SOX4 | up-regulates
|
Proliferation |
0.7 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-260133 |
|
|
Homo sapiens |
Acute Myeloid Leukemia Cell |
| pmid |
sentence |
| 24183681 |
These data demonstrate an HSC cell intrinsic role for Sox4 on proliferation induced by loss of C/EBPα. |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| Pathways: | Acute Myeloid Leukemia, AML1-ETO in AML, FLT3 in AML, AML_TRIPLETS, Triple mutant AML |
| + |
IL5RA | up-regulates activity
binding
|
SOX4 |
0.429 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-223010 |
|
|
Mus musculus |
Pro-B-lymphocyte |
| pmid |
sentence |
| 11498591 |
Sox4 activation by IL-5R_ appears to be direct, with syntenin functioning as an adaptor molecule. Syntenin mediates IL-5induced Sox4 activation. |
|
| Publications: |
1 |
Organism: |
Mus Musculus |
| + |
SOX4 | down-regulates 
|
Differentiation |
0.7 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-255676 |
|
|
Homo sapiens |
Leukemia Cell |
| pmid |
sentence |
| 24183681 |
Collectively, our experiments identified the oncogene Sox4 as a factor mediating increased serial-replating ability and blocked differentiation of Cebpa-deficient progenitors. |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| Pathways: | Acute Myeloid Leukemia, AML1-ETO in AML, FLT3 in AML, AML_TRIPLETS, Triple mutant AML |
| + |
SDCBP | up-regulates activity
binding
|
SOX4 |
0.554 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-223089 |
|
|
Mus musculus |
Pro-B-lymphocyte |
| pmid |
sentence |
| 11498591 |
Sox4 activation by IL-5R_ appears to be direct, with syntenin functioning as an adaptor molecule. Syntenin mediates IL-5induced Sox4 activation. |
|
| Publications: |
1 |
Organism: |
Mus Musculus |
| + |
SOX4 | up-regulates quantity
transcriptional regulation
|
DICER1 |
0.406 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-258987 |
|
|
Homo sapiens |
Melanoma Cell |
| pmid |
sentence |
| 22689055 |
.... showed that Sox4 positively regulates Dicer expression by binding to its promoter sequences and enhancing its activity. We found that knockdown of Dicer enhances the matrigel invasion of melanoma cells by at least twofold. In addition, we revealed that overexpression of exogenous Dicer reverts the enhanced melanoma cell invasion upon Sox4 knockdown |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| + |
CEBPA | down-regulates 
transcriptional regulation
|
SOX4 |
0.392 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-255675 |
|
|
Homo sapiens |
|
| pmid |
sentence |
| 24183681 |
In summary, our data demonstrate that C/EBPα negatively regulates Sox4 transcription via direct DNA-binding. |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| Pathways: | Acute Myeloid Leukemia, AML1-ETO in AML, FLT3 in AML, AML_TRIPLETS, Triple mutant AML |
3.0
SOX4
- 
- 